Hyperglycemia should be Avoided in Critical Illness and the Postoperative Period

Kalpana Muthusamy, John M. Miles

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Recent evidence from large clinical trials has cast into doubt the benefit of intensive insulin therapy to control hyperglycemia in the critically ill, and has in some instances shown harm from attempts to aggressively lower blood glucose. We argue that adverse results are linked to the occurrence of hypoglycemia, a problem made worse by excessively ambitious glucose targets in the context of an inappropriate definition of hypoglycemia (≤2.2 mmol/L) and methodology for point-of-care testing of blood glucose that lacks precision and accuracy. With an appropriate glucose target and careful avoidance of hypoglycemia, intensive therapy is safe and likely to benefit critically ill patients with hyperglycemia. We endorse the ADA/AACE current recommended glucose target range of 7.8-10.0 mmol/L

Original languageEnglish (US)
Title of host publicationClinical Dilemmas in Diabetes
PublisherWiley-Blackwell
Pages134-144
Number of pages11
ISBN (Print)9781405169288
DOIs
StatePublished - Mar 31 2011

Fingerprint

Hypoglycemia
Postoperative Period
Critical Illness
Hyperglycemia
Glucose
Blood Glucose
Clinical Trials
Insulin
Therapeutics

Keywords

  • Critical illness
  • Hypoglycemia
  • Intensive care
  • Intensive insulin therapy
  • Nutritional support

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Muthusamy, K., & Miles, J. M. (2011). Hyperglycemia should be Avoided in Critical Illness and the Postoperative Period. In Clinical Dilemmas in Diabetes (pp. 134-144). Wiley-Blackwell. https://doi.org/10.1002/9781444340280.ch15

Hyperglycemia should be Avoided in Critical Illness and the Postoperative Period. / Muthusamy, Kalpana; Miles, John M.

Clinical Dilemmas in Diabetes. Wiley-Blackwell, 2011. p. 134-144.

Research output: Chapter in Book/Report/Conference proceedingChapter

Muthusamy, K & Miles, JM 2011, Hyperglycemia should be Avoided in Critical Illness and the Postoperative Period. in Clinical Dilemmas in Diabetes. Wiley-Blackwell, pp. 134-144. https://doi.org/10.1002/9781444340280.ch15
Muthusamy K, Miles JM. Hyperglycemia should be Avoided in Critical Illness and the Postoperative Period. In Clinical Dilemmas in Diabetes. Wiley-Blackwell. 2011. p. 134-144 https://doi.org/10.1002/9781444340280.ch15
Muthusamy, Kalpana ; Miles, John M. / Hyperglycemia should be Avoided in Critical Illness and the Postoperative Period. Clinical Dilemmas in Diabetes. Wiley-Blackwell, 2011. pp. 134-144
@inbook{bb6e448a7ea8430cb8cbea280af19a94,
title = "Hyperglycemia should be Avoided in Critical Illness and the Postoperative Period",
abstract = "Recent evidence from large clinical trials has cast into doubt the benefit of intensive insulin therapy to control hyperglycemia in the critically ill, and has in some instances shown harm from attempts to aggressively lower blood glucose. We argue that adverse results are linked to the occurrence of hypoglycemia, a problem made worse by excessively ambitious glucose targets in the context of an inappropriate definition of hypoglycemia (≤2.2 mmol/L) and methodology for point-of-care testing of blood glucose that lacks precision and accuracy. With an appropriate glucose target and careful avoidance of hypoglycemia, intensive therapy is safe and likely to benefit critically ill patients with hyperglycemia. We endorse the ADA/AACE current recommended glucose target range of 7.8-10.0 mmol/L",
keywords = "Critical illness, Hypoglycemia, Intensive care, Intensive insulin therapy, Nutritional support",
author = "Kalpana Muthusamy and Miles, {John M.}",
year = "2011",
month = "3",
day = "31",
doi = "10.1002/9781444340280.ch15",
language = "English (US)",
isbn = "9781405169288",
pages = "134--144",
booktitle = "Clinical Dilemmas in Diabetes",
publisher = "Wiley-Blackwell",

}

TY - CHAP

T1 - Hyperglycemia should be Avoided in Critical Illness and the Postoperative Period

AU - Muthusamy, Kalpana

AU - Miles, John M.

PY - 2011/3/31

Y1 - 2011/3/31

N2 - Recent evidence from large clinical trials has cast into doubt the benefit of intensive insulin therapy to control hyperglycemia in the critically ill, and has in some instances shown harm from attempts to aggressively lower blood glucose. We argue that adverse results are linked to the occurrence of hypoglycemia, a problem made worse by excessively ambitious glucose targets in the context of an inappropriate definition of hypoglycemia (≤2.2 mmol/L) and methodology for point-of-care testing of blood glucose that lacks precision and accuracy. With an appropriate glucose target and careful avoidance of hypoglycemia, intensive therapy is safe and likely to benefit critically ill patients with hyperglycemia. We endorse the ADA/AACE current recommended glucose target range of 7.8-10.0 mmol/L

AB - Recent evidence from large clinical trials has cast into doubt the benefit of intensive insulin therapy to control hyperglycemia in the critically ill, and has in some instances shown harm from attempts to aggressively lower blood glucose. We argue that adverse results are linked to the occurrence of hypoglycemia, a problem made worse by excessively ambitious glucose targets in the context of an inappropriate definition of hypoglycemia (≤2.2 mmol/L) and methodology for point-of-care testing of blood glucose that lacks precision and accuracy. With an appropriate glucose target and careful avoidance of hypoglycemia, intensive therapy is safe and likely to benefit critically ill patients with hyperglycemia. We endorse the ADA/AACE current recommended glucose target range of 7.8-10.0 mmol/L

KW - Critical illness

KW - Hypoglycemia

KW - Intensive care

KW - Intensive insulin therapy

KW - Nutritional support

UR - http://www.scopus.com/inward/record.url?scp=84884770807&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884770807&partnerID=8YFLogxK

U2 - 10.1002/9781444340280.ch15

DO - 10.1002/9781444340280.ch15

M3 - Chapter

AN - SCOPUS:84884770807

SN - 9781405169288

SP - 134

EP - 144

BT - Clinical Dilemmas in Diabetes

PB - Wiley-Blackwell

ER -